Precision Prostate Cancer Diagnosis: The Role of MRI and Targeted Biopsy

Jump To Section

• MRI Revolutionizes Prostate Cancer Diagnosis
• From Uncertainty to 95% Certainty in Cancer Grading
• Enabling Molecular and Genetic Cancer Testing
• MRI-Ultrasound Fusion-Guided Biopsy Technique
• Clinical Impact on Prostate Cancer Treatment Decisions
• The Future of Image-Guided Prostate Cancer Care

MRI Revolutionizes Prostate Cancer Diagnosis

Prostate cancer diagnostics have finally caught up with cancer diagnosis in other organs, thanks to the integration of advanced imaging. Dr. Mark Emberton, MD, confirms that multiparametric MRI of the prostate is now a cornerstone of modern urological practice. This diagnostic progress allows for more targeted cancer detection and significantly improves risk stratification, a critical advancement in a field historically plagued by diagnostic uncertainty.

The technology provides what was missing for a hundred years: precise cancer location inside the prostate gland. According to Dr. Emberton, this anatomical precision fundamentally changes how urologists approach prostate cancer, moving from guesswork to certainty.

From Uncertainty to 95% Certainty in Cancer Grading

Historically, prostate cancer diagnosis was fraught with potential errors because physicians could never be sure of the cancer's full extent within the prostate. Dr. Mark Emberton, MD, explains that treatment was often performed "just in case" there was more aggressive cancer present. The paradigm has now shifted dramatically with MRI-guided precision.

Dr. Mark Emberton, MD, states, "We can now say, 'I have a 95% certainty that you have a prostate cancer of this grade and volume'." This extraordinary precision comes from the ability to identify the carcinoma tumor, place a needle directly inside it, and obtain truly representative tissue samples, transforming patient consultations from estimations to evidence-based discussions.

Enabling Molecular and Genetic Cancer Testing

The precision of MRI-guided biopsy doesn't just improve anatomical accuracy—it unlocks the potential for sophisticated molecular analysis. Dr. Mark Emberton, MD, emphasizes that by obtaining centimeters of cancer tissue instead of millimeters, pathologists can now perform comprehensive genetic testing and evaluate new molecular cancer markers.

This abundance of tissue allows for subjecting prostate samples to genetic testing, molecular proliferation testing, and all the new molecular cancer markers currently emerging. Dr. Emberton contrasts this with historical approaches where blind biopsies might only yield a tiny bit of tissue if they happened to hit the cancer at all, severely limiting diagnostic capabilities.

MRI-Ultrasound Fusion-Guided Biopsy Technique

While biopsy inside an MRI magnet is possible, Dr. Mark Emberton, MD, explains that practical constraints make this approach challenging for most clinical settings. MRI scanners are in short supply globally and offer limited working space. Instead, most urologists are adopting image-to-image co-registration techniques.

This process involves using computer science to merge MRI information with real-time ultrasound imaging. As Dr. Emberton describes, "We then use computer science to re-register MRI information on the ultrasound." This fusion allows physicians to access all prostate cancer location data during an office-based procedure using readily available ultrasound equipment, with approximately 7-9 companies now offering commercial solutions for this technology.

Clinical Impact on Prostate Cancer Treatment Decisions

The precision afforded by MRI-guided prostate cancer diagnosis directly translates to more rational treatment discussions. Dr. Mark Emberton, MD, emphasizes that with accurate knowledge of cancer grade and volume, physicians and patients can have informed conversations about whether to pursue active treatment or implement careful monitoring protocols.

Dr. Anton Titov, MD, notes that this approach reflects the broader understanding that cancer represents many different diseases with distinct molecular characteristics. The ability to precisely locate and sample prostate tumors enables treatment planning that is tailored to the individual's specific cancer profile rather than applying one-size-fits-all approaches based on incomplete information.

The Future of Image-Guided Prostate Cancer Care

The integration of multiparametric MRI into prostate cancer diagnostics represents a fundamental shift toward precision medicine. Dr. Mark Emberton, MD's insights reveal how this technology has moved prostate cancer care from uncertainty to confidence, enabling both anatomical and molecular precision.

As these techniques become more widespread through commercial image-fusion platforms, patients can expect more accurate diagnoses, reduced unnecessary procedures, and treatment plans precisely tailored to their specific cancer characteristics. This advancement finally brings prostate cancer diagnosis in line with other oncology specialties that have long benefited from precise imaging guidance.

Full Transcript

Dr. Anton Titov, MD: MRI in prostate cancer diagnosis: prostate MRI vs biopsy. MRI helps to avoid non-diagnostic and unnecessary biopsy. Multiparametric MRI of prostate must be done.

So the diagnostics of prostate cancer recently has caught up with cancer diagnosis in other organs. The diagnostic progress has been made earlier in other organs. That allows more targeted diagnostics and more targeted cancer treatment.

Dr. Mark Emberton, MD: Correct! And also, we have better risk stratification for prostate cancer. It's a big word. But we used to make many errors in prostate cancer diagnosis. It meant that we were never really sure what cancer was in the prostate.

So when we found a little bit of cancer in the prostate, there was always possibility there could be more cancer. Therefore the prostate cancer treatment was done "just in case".

Now we can have extraordinary precision because we can identify the prostate carcinoma tumor. We can put the needle inside the tumor and get representative tissue. We can actually know exactly what's in the prostate cancer.

And so instead of saying, "I think you have a low-risk cancer, Sir", we can now say, "I have a 95% certainty that you have a prostate cancer of this grade and volume". So it's the precision medicine now that makes all the difference in cancer diagnosis.

If we were having a conversation about care, I would be able to say to you exactly what was in your prostate. We can have a rational discussion about how best to treat cancer. Whether to leave prostate cancer alone, whether to watch it very carefully.

If we were going to treat cancer in the prostate, how we might approach the treatment.

Dr. Anton Titov, MD: So this reflects the trend that cancer is many different diseases of distinct molecular characteristics. Therefore, to say, "You have cancer of this organ", prostate cancer, in this case, is not sufficient anymore. Cancer diagnosis has to be sophisticated and diagnosed at the molecular level and at precise anatomical level.

Dr. Mark Emberton, MD: Correct. So, the prostate gland anatomy we've talked about. We get really representative prostate tissue now during biopsy. We get also a lot of tissue.

This means that we can subject that tissue to genetic testing, to molecular proliferation testing. We can test all new molecular cancer markers that are coming out now. We can subject lots of prostate gland tissue to genetic cancer tests.

So historically, because you didn't know where the cancer was, we used to spread the biopsy needles. If there was a cancer there, you're lucky if you hit it once and you get a tiny bit of tissue.

Now we know where prostate cancer is exactly. So you fire needles at it. So instead of giving one millimeter of cancer to the pathologist, we can now give a centimeter or two centimeters of cancer to pathologist. That allows us to undertake all these new genetic cancer tests.

Dr. Anton Titov, MD: You have already elaborated on that. But this is precisely the role for MRI in guiding prostate cancer biopsy.

Dr. Mark Emberton, MD: Correct. MRI gives us what has been missing for hundred years. It is a cancer location inside prostate gland. Then we can use and exploit cancer location in two ways.

One method is to do the biopsy in the MRI magnet. Some people are doing that. But MRI is a very tight space. There's not a lot of space inside MRI to work in.

MRI time in most countries is in short supply. Most MRI scanners are full. So prostate biopsy inside MRI is quite challenging.

If you have an abundance of MRI scanners, which they do in some countries, particularly in Japan, and maybe in some cities within Europe, most of us are taking the information from MRI. We then use computer science to re-register MRI information on the ultrasound.

We could have an ultrasound in this room, one we're speaking in. You don't need any special equipment. But we certainly couldn't have an MRI scanner in this room.

And then you use the ultrasound scan and then merge the MRI information onto the ultrasound scan. This gives you all the information about prostate cancer in real time in your office.

And so that's the way that most of us are going prostate cancer diagnosis. That's called image to image co-registration. There are about 7 or 8, maybe even 9 companies now offering commercial solutions for urologists and oncologists to get information location from one platform to another.

Dr. Anton Titov, MD: So this helps precise diagnosis. Therefore, it helps to identify a precise prostate cancer treatment plan for that patient.

Dr. Mark Emberton, MD: Correct!